Screening for hepatocellular carcinoma: why, when, how?
Hepatocellular carcinoma (HCC) is a major public health concern in many areas of the world, and its incidence is increasing in the United States and other countries. Screening for HCC in patients with cirrhosis has been advocated to identify those with small lesions who would benefit from transplantation or surgical resection. Despite these recommendations, several issues regarding screening remain controversial. No randomized, controlled trials have confirmed that surveillance for HCC reduces disease-specific mortality. In addition, the most appropriate screening test and optimal screening interval have not yet been defined. Clearly, these unresolved questions have a major impact on the cost-effectiveness of a screening program either at the population or the clinic level. A few studies, however, have suggested that screening may be cost-effective because a minor survival benefit could result in a cost that is acceptable to decision makers.
Arguedas
Miguel R
MR
Division of Gastroenterology and Hepatology, Department of Medicine, University of Alabama at Birmingham, MCLM 281, 1918 University Boulevard, Birmingham, AL 35294, USA. Arguedas@uab.edu
D015415:Biomarkers / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000191:economics; D003362:Cost-Benefit Analysis; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000191:economics; D008279:Magnetic Resonance Imaging; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed; D000509:alpha-Fetoproteins / Q000032:analysis
D015415:Biomarkers; D000509:alpha-Fetoproteins